Welcome to our dedicated page for Neumora Therapeutics news (Ticker: NMRA), a resource for investors and traders seeking the latest updates and insights on Neumora Therapeutics stock.
Neumora Therapeutics, Inc. develops clinical-stage biopharmaceutical programs for brain diseases and other underserved, prevalent diseases. News for NMRA centers on neuroscience drug development, financial results, business updates, and presentations at healthcare conferences.
Recurring updates describe pipeline programs such as navacaprant for major depressive disorder, NMRA-511 for Alzheimer’s disease agitation, M4 muscarinic receptor positive allosteric modulators including NMRA-861 and NMRA-898, and NMRA-215, an oral brain-penetrant NLRP3 inhibitor. Company announcements also cover clinical study results, development strategy, cash runway commentary, and program prioritization across neuropsychiatric and neurodegenerative disease areas.
Neumora Therapeutics (NMRA) reported Q2 2024 financial results and provided a business update. Key highlights include:
1. Phase 3 KOASTAL-1 study data for navacaprant in major depressive disorder (MDD) expected in Q4 2024.
2. Ongoing clinical studies in MDD, bipolar depression, and Alzheimer's disease agitation.
3. Strong financial position with $371.6 million in cash, cash equivalents, and marketable securities, expected to support operations into 2026.
4. Q2 2024 R&D expenses increased to $48.6 million from $32.8 million in Q2 2023.
5. Net loss for Q2 2024 was $58.7 million, compared to $38.5 million in Q2 2023.
6. Narrowed guidance to submit an IND for an additional M4 compound in H1 2025.
Neumora Therapeutics has initiated a Phase 1b study evaluating NMRA-511 for treating agitation in Alzheimer's disease (AD). NMRA-511, an oral antagonist of the vasopressin 1a receptor (V1aR), was well-tolerated in prior studies with no serious adverse events. The Phase 1b study, starting with healthy elderly adults and then AD patients, aims to assess safety, tolerability, and efficacy. The study will measure changes in agitation using the Cohen-Mansfield Agitation Inventory. Neumora expects to report topline data in the second half of 2025.
Neumora Therapeutics has initiated a Phase 2 clinical trial for navacaprant, targeting bipolar depression. The company aims to evaluate the safety and efficacy of the 80 mg oral KOR antagonist, which previously showed promise in treating major depressive disorder (MDD). The trial will involve 60 patients and focus on improvements in depressive symptoms and anhedonia, with results expected in the second half of 2025. Additionally, navacaprant is in Phase 3 development for MDD, with data from the KOASTAL-1 study anticipated in Q4 2024. This study could lead to broader applications for navacaprant in bipolar disorder.
Neumora Therapeutics, Inc. (Nasdaq: NMRA) reported strong financial results for Q1 2024 with $423.0 million in cash, guidance narrowed to Q4 2024 for Phase 3 data from KOASTAL-1 study with navacaprant in MDD, and multiple upcoming clinical study initiations. The company is well-positioned with a robust pipeline targeting neuropsychiatric and neurodegenerative diseases.
Neumora Therapeutics, Inc. (Nasdaq: NMRA) will participate in two investor conferences in May: BofA Securities Healthcare Conference 2024 and RBC Capital Markets Global Healthcare Conference. The company's therapeutic pipeline includes seven clinical and pre-clinical brain disease programs.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.